Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial

Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial

Sachio Fushida,1 Jun Kinoshita,1 Masahide Kaji,2 Katsunobu Oyama,1 Yasuo Hirono,3 Tomoya Tsukada,2 Takashi Fujimura,4 Tetsuo Ohta1 On behalf of the Digestive Disease Support Organization Study Group 1Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, 2Department of...

Full description

Bibliographic Details
Main Authors: Fushida S, Kinoshita J, Kaji M, Oyama K, Hirono Y, Tsukada T, Fujimura T, Ohta T
Format: Article
Language:English
Published: Dove Medical Press 2016-07-01
Series:Drug Design, Development and Therapy
Subjects:
valproic acid
paclitaxel
second- or third-line therapy
advanced gastric cancer
Online Access:https://www.dovepress.com/paclitaxel-plus-valproic-acid-versus-paclitaxel-alone-as-second--or-th-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/paclitaxel-plus-valproic-acid-versus-paclitaxel-alone-as-second--or-th-peer-reviewed-article-DDDT

Similar Items